RICHTER SYNDROME
Clinical trials for RICHTER SYNDROME explained in plain language.
Never miss a new study
Get alerted when new RICHTER SYNDROME trials appear
Sign up with your email to follow new studies for RICHTER SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo shows promise for aggressive blood cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 07:43 UTC
-
Experimental cocktail targets aggressive blood cancer
Disease control OngoingThis early-phase study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to prior treatments. The main goals are to find the safest dose and identify side e…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:41 UTC
-
New drug duo shows promise for tough blood cancers
Disease control OngoingThis study tests a combination of two drugs, duvelisib and venetoclax, in people with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or Richter's Syndrome. The goal is to see if the combo can shrink or control the cancer. About 55 adults who have already tried at le…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 07:23 UTC
-
New Triple-Drug attack shows promise against tough lymphomas
Disease control OngoingThis study tests a new drug combination (ALX148, rituximab, and lenalidomide) in people with slow-growing or fast-growing B-cell non-Hodgkin lymphoma that has not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink or eliminate tumors. …
Matched conditions: RICHTER SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New triple therapy aims to wipe out Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…
Matched conditions: RICHTER SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
Scientists dig deeper into epcoritamab's effects on hard-to-treat blood cancers
Knowledge-focused OngoingThis study looks at blood, bone marrow, and lymph node samples from people with chronic lymphocytic leukemia or Richter syndrome who are receiving epcoritamab. The goal is to learn how the drug affects immune cells and cancer cells over time. Only 5 people are taking part, and th…
Matched conditions: RICHTER SYNDROME
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated May 22, 2026 14:01 UTC